Pivotal Study of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema (DIAMOND-1)

Last updated: November 14, 2024
Sponsor: Oculis
Overall Status: Active - Recruiting

Phase

2/3

Condition

Macular Edema

Diabetic Retinopathy

Diabetic Macular Edema

Treatment

Vehicle

Dexamethasone ophthalmic suspension (OCS-01)

Clinical Study ID

NCT05066997
DX219
  • Ages 18-85
  • All Genders

Study Summary

The primary objective is to evaluate the efficacy and safety of OCS 01 as compared to Vehicle in subjects with Diabetic Macular Edema (DME).

Eligibility Criteria

Inclusion

Inclusion Criteria (selection) - Stage 1:

  1. Have a signed informed consent form before any study-specific procedures are performed.

  2. Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with central subfield thickness (CST) of ≥310 µm by SD-OCT at screening (Visit 1) (as assessed by an independent reading center).

  3. Have a documented diagnosis of type 1 or type 2 diabetes mellitus at Visit 1 (Screening).

Inclusion Criteria (selection) - Stage 2:

  1. Have a signed informed consent form before any study-specific procedures are performed.

  2. Have DME with presence of intraretinal and/or subretinal fluid in the study eye, with central subfield thickness (CST) of ≥310 µm by SD-OCT at screening (Visit 1) (as assessed by an independent reading center).

  3. Have a documented diagnosis of type 1 or type 2 diabetes mellitus prior to Visit 1 (Screening).

Exclusion criteria (selection) - Stage 1 and Stage 2:

  1. Have macular edema considered to be because of a cause other than DME.

  2. Have a decrease in BCVA because of causes other than DME.

  3. Have a known history of significant macular ischemia which would prevent gain in visual acuity in the study eye.

Study Design

Total Participants: 497
Treatment Group(s): 2
Primary Treatment: Vehicle
Phase: 2/3
Study Start date:
October 19, 2021
Estimated Completion Date:
June 30, 2026

Study Description

A Phase 2/3 Pivotal Double-masked, Randomized, 2 stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema

Stage 1: To select a dosing regimen for OCS-01 in subjects with DME, and evaluate the efficacy and safety of OCS-01 as compared to Vehicle at Week 12 in subjects with DME.

Stage 2: To evaluate the efficacy and safety of OCS-01 as compared to Vehicle at Week 52 in subjects with DME.

Connect with a study center

  • Oculis Investigative Site

    Beverly Hills, California 90211
    United States

    Site Not Available

  • Oculis Investigative Site - Retina Vitreous Associates Medical Group

    Beverly Hills, California 90211
    United States

    Site Not Available

  • Oculis Investigative Site: University Retina - Lemont

    Lemont, Illinois 60439
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.